Description
Management of both acute and chronic neurologic diseases can be challenging for both the patient and the health care provider. Many neurologic disorders involve progressive deterioration in physical and mental capabilities, which can be devastating to the patient and the patient’s family. In many respects, neurotherapeutics represent the largest as-yet untapped market in medicine.
This Kalorama Information report focuses on several key product segments of neurotherapeutic treatment:
- Alzheimer’s Disease and Other Dementias
- Brain and Neurologic Cancers
- Brain Trauma and Stroke
- Movement Disorders
- Seizure Disorders and Epilepsy
- Spinal Cord and Peripheral Nerve Disorders
- Other Neurological Conditions and Disorders
The report covers both currently marketed and late-stage development neurotherapeutic products in detail. Revenues for each segment were generated using dollar and unit sales for each product.
The report includes statistical information for selected neurological conditions and diseases by type worldwide, with special emphasis on the U.S. market. The market segments provide an overview, description of products on the market, description of products in development, market estimates and forecasts, and competitive analysis of leading providers. The report also includes current issues and trends affecting the industry.
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertain to the world market at the manufacturers’ level. The base year for data was 2004. Historical data are provided for the years 2002 and 2003, with forecast data provided for 2005 through 2009. Compound annual growth rates (CAGRs) are provided for the 2002-2004, 2004-2009 and 2002-2009 periods for each industry segment covered. Competitive analysis is provided for the year 2004. The forecasted market analysis for 2005-2009 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends.
Diseases addressed in this study include:
- Alzheimer’s Disease
- Amyotrophic Lateral Sclerosis
- Bell’s Palsy
- Traumatic Brain Injury (TBI)
- Brain and Spinal Tumors
- Carpal Tunnel Syndrome
- Cerebral Palsy
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Creutzfeldt-Jakob Disease
- Epilepsy
- Guillain-Barre Syndrome
- Huntington’s Disease
- Migraine Headaches
- Motor Neuron Diseases
- Multi-Infarct Dementia
- Multiple Sclerosis
- Myasthenia Gravis
- Neurofibromatosis
- Parkinson’s Disease
- Spinal Cord Injury
- Stroke
Table of Contents
Chapter One: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
Chapter Two: Introduction
- Structural Organization of the Neurological System
- Central Nervous System
- The Brain
- Spinal Cord
- Peripheral Nervous System
- Autonomic Nervous System
- Neurons and Supportive Cells
- Neurons
- Glia
- Neurotransmitters
- Aging
- Types of Neurological Diseases and Disorders
- Demographics and Statistics
Chapter Three: Alzheimer’s Disease and Other Dementias
- Overview
- Description of Products
- Acetylcholinesterase Inhibitors
- Tacrine (Cognex—First Horizon)
- Donepezil (Aricept—Eisai)
- Rivastigmine (Exelon—Novartis)
- Galanthamine (Reminyl—Janssen Pharmaceutica)
- N-Methyl-d-aspartate (NMDA)
- Memantine (Namenda—Forest Labs, Ebixa—Lundbeck)
- Nootropic Drugs
- Ergoloid Mesylates (Hydergine—Novartis)
- Piracetam (Nootropil—UCB Company)
- Nicergoline (Sermion—Pfizer)
- Aniracetam (Ampamet—Biogenesis Laboratories)
- Research and Development
- Ebixa
- Alcar
- Alzhemed
- Phenserine
- Xaliproden
- ABT-890
- Agilect
- Avandia
- CX717
- Flurizan
- Leuprolide
- MEM 3454
- MKC-231
- NS2330
- 189254
- Phosiphen
- Market Size and Growth
- Competitive Analysis
Chapter Four: Brain and Neurologic Cancers
- Overview
- Description of Products
- BCNU (Gliadel Wafer—Guilford Pharmaceuticals)
- Floxuridine (FUDR—Mayne Pharma; Various Others)
- Doxorubicin (Adriamycin—Pfizer; Rubex—Bristol-Myers Squibb)
- Temozolomide (Temodar—Schering)
- Research and Development
- Efaproxyn
- IL-13-PE38
- TheraCIM
- TransMID
- Xerecept
- Cerepro
- Cervene
- Cotara
- Tarceva
- Xcytrin
- Market Size and Growth
- Competitive Analysis
Chapter Five: Brain Trauma and Stroke
- Overview
- Traumatic Brain Injury
- Primary Injury
- Secondary Injury
- Cerebrovascular Disease and Stroke
- Ischemic Stroke
- Hemorrhagic Stroke
- Description of Products
- Ticlopidine (Ticlid—Sanofi-Aventis and Roche)
- Nimodipine (Nimotop—Bayer)
- Nicergoline (Sermion—Tanabe)
- tPA (Activase—Genentech)
- Research and Development
- Cerovive
- ReoPro
- Argatroban
- Cerebril
- Desmoteplase
- NovoSeven
- SonoLysis
- Traxoprodil
- 737004
- 234551
- Market Size and Growth
- Competitive Analysis
Chapter Six: Movement Disorders
- Overview
- Parkinson’s Disease
- Huntington’s Disease
- Myasthenia Gravis
- Tic and Tourette’s Syndrome
- Periodic Limb Movement Disorder and Restless Leg Syndrome
- Description of Products
- Anticholinergic Agents
- Biperiden hydrochloride (Akineton—Bristol-Myers Squibb)
- Trihexyphenidyl HCl (Artane—Wyeth)
- Benztropine mesylate (Cogentin—Merck)
- Hyoscyamine sulfate (Levbid—Schwarz)
- Catechol-O-Methyltransferase Inhibitors
- Entacapone (Comtan—Novartis)
- Tolcapone (Tasmar—Valeant Pharmaceuticals/Roche)
- Dopaminergic Agents
- Carbidopa (Lodosyn—Bristol-Myers Squibb)
- Pramipexole (Mirapex—Pfizer and Boehringer Ingelheim)
- Pergolide (Permax—Amirin)
- Ropinirole hydrochloride (Requip—GlaxoSmithKline)
- Carbidopa/Levodopa (Sinemet—Bristol-Myers Squibb)
- Carbidopa-levodopa (Parcopa—Schwarz)
- Carbidopa-levodopa (Duodopa—Solvay)
- Amantadine (Symmetrel—Endo Labs)
- Bromocriptine (Parlodel—Novartis)
- Cabergoline (Cabasar—Pfizer)
- Tetrabenazine (Nitoman—Roche; Xenazine—Cambridge Laboratories)
- Monoamine Oxidase Inhibitor
- Selegiline HCl (Eldypryl—Somerset)
- Selegiline (Zelapar—Valeant Pharmaceuticals)
- Rasagiline (Azilect—Lundbeck/TEVA)
- Others
- Pyridostigmine bromide (Mestinon—Valeant Pharmaceuticals)
- Edrophonium (Tensilon—Valeant Pharnaceuticals)
- Ambenonium Chloride (Mytelase—Sanofi-Aventis ) Neostigmine (Prostigmin—Valeant Pharmaceuticals)
- Research and Development
- Azilect
- Neupro
- Tetrabenazine
- Zelapar (Selegiline)
- CEP 1347
- KW-6002
- Miraxion
- Requip CR
- SLV308
- Market Size and Growth
- Competitive Analysis
Chapter Seven: Seizure Disorders and Epilepsy
- Overview
- Generalized Seizures
- Partial Seizures
- Aura/Prodrome
- Description of Products
- Barbiturates
- Pentobarbital (Nembutal—Abbott)
- Benzodiazepines
- Clonazepam (Klonopin, Rivotril—Roche)
- Clorazepate (Tranxene—Abbott)
- Diazepam (Valium—Roche)
- GABA analogues
- Tiagabine HCl (Gabitril—Cephalon)
- Gabapentin (Neurontin—Pfizer)
- Hydantoins
- Fosphenytoin sodium (Cerebyx—Pfizer)
- Phenytoin sodium (Dilantin—Pfizer)
- Phenytoin (Phenytek—Bertek)
- Miscellaneous
- Carbamazepine (Carbatrol—Shire)
- Valproate sodium (Depacon—Abbott)
- Valproic acid (Depakene—Abbott)
- Felbamate (Felbatol—Wallace)
- Levetiracetam (Keppra—UCB)
- Carbamazepine (Tegretol—Novartis)
- Topiramate (Topamax—Ortho-McNeil)
- Oxcarbazepine (Trileptal—Novartis)
- Zonisamide (Zonegran—Elan)
- Phenyltriazines
- Lamotrigine (Lamictal—GlaxoSmithKline)
- Succinimides
- Methsuximide (Celontin—Pfizer)
- Ethosuximide (Zarontin—Pfizer)
- Vigabatrin (Sabril—Sanofi-Aventis)
- Research and Development
- Keppra (levetiracetam)
- Lyrica (pregabalin)
- Topomax (topiramate)
- Lacosamide
- Retigabine
- Market Size and Growth
- Competitive Analysis
Chapter Eight: Spinal Cord and Peripheral Nerve Disorders
- Overview
- Multiple Sclerosis
- Amyotrophic Lateral Sclerosis
- Spinal Cord Injury
- Guillian-Barre Syndrome
- Bell’s Palsy
- Description of Products
- Interferon Beta (Avonex—Biogen)
- Interferon Beta-1b (Betaseron—Schering)
- Glatiramer Acetate (Copaxone—TEVA Neuroscience)
- Depo-Medrol (Pfizer)
- Mitoxantrone HCl (Novantrone—Immunex)
- Prednisolone (Pediapred—Celltech)
- Interferon Beta (Rebif—Serono)
- Methylprednisolone sodium succinate (Solu-Medrol—Pfizer)
- Riluzole (Rilutek—Sanofi-Aventis)
- Baclofen (Lioresol—Watson) Tizanadine (Zanaflex—Athena)
- Research and Development
- Antegren (now called Tysabri)
- Neurodex
- Campath-1H
- Fampridine
- Mylinax
- 683699
- Teriflunomide
- Market Size and Growth
- Competitive Analysis
Chapter Nine: Other Neurological Conditions and Diseases
- Overview
- Migraine Headaches
- Neurofibromatosis
- Neuropathies
- Trigeminal Neuralgia
- Postherpetic Neuralgia
- Description of Products
- Serotonin Receptor Agonists
- Naratriptan (Amerge—GlaxoSmithKline)
- Sumatriptan (Imitrex—GlaxoSmithKline)
- Rizatriptan (Maxalt—Merck)
- Zolmitriptan (Zomig—AstraZeneca )
- Eletriptan (Relpax—Pfizer)
- Almotriptan Malate (Axert—Ortho-McNeil Pharmaceutical)
- Frovatriptan succinate (Frova—Endo)
- Ergot Alkaloids
- Ergotamine with Caffeine (Cafergot—Sandoz )
- Dihydroergotamine mesylate (Migranal—Valeant Pharmaceuticals)
- Beta Andrenergic Blocking Agents
- Timolol Maleate (Blocadren—Merck), Propranolol HCl (Inderal—Wyeth)
- Isometheptene & Others
- Isometheptene mucate, Dichloralphenazone, Acetaminophen (Midrin—Carnick)
- Topiramate (Topamax—Johnson & Johnson)
- Research and Development
- MT 100
- MT 300
- Trexim
- Acetyl-L-carnitine
- Botox
- BIBN4096 BS
- Market Size and Growth
- Competitive Analysis
Chapter Ten: Issues and Trends Affecting the Neurotherapeutic Drug Market
- Introduction
- Disease Modifying Agents
- Stem Cell Research and Neurological diseases
- BioMarkers
- Early Diagnosis
- Estrogen and Cognitive Function
- Cholesterol and Alzheimer’s Disease
- Nerve Growth Factor Gene Therapy
- Individualized Treatment
- Vitamin Role in Alzheimer’s Disease
- Management of Brain Tumors
- Genetic Therapy
- Alzheimer’s Prevention Initiative
Chapter Eleven: Market Summary
- Overview
- Total Market Size and Forecast
Chapter Twelve: Corporate Profiles
- Introduction
- Abbott Laboratories
- AstraZeneca plc
- Biogen IDEC, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Eisai, Inc
- GlaxoSmithKline
- Johnson & Johnson Group
- Merck & Company, Inc.
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc.
- Roche
- Sanofi-Aventis
- Schering AG
- Schering-Plough Corporation
- Serono
- TEVA
Appendix: Company Directory
List of Exhibits
Chapter One: Executive Summary
- Table 1-1: The World Market for Neurotherapeutic Drugs 2002-2009
- Figure 1-1: The World Market for Neurotherapeutic Drugs 2002-2009
Chapter Two: Introduction
- Table 2-1: Neurologic Conditions and Diseases by Chapter in This Study
- Table 2-2: Estimated World Prevalence, Incidence and Mortality of Selected Neurological Conditions and Diseases
- Figure 2-1: Estimated World Prevalence of Top Neurological Conditions and Diseases
- Table 2-3: World Population by Selected Geographical Region (Africa, Asia, Europe, North America, Oceania, South America) 2004-2050
- Figure 2-2: World Population by Selected Geographical Region 2004-2050
- Table 2-4: Estimated World Population by Age and Geographical Region, 2004
- Figure 2-3: Estimated World Population by Age and Geographical Region, 2004
Chapter Three: Alzheimer’s Disease and Other Dementias
- Table 3-1: Currently Available Alzheimer’s’s Disease and Dementia Treatments (Type, Brand, and Manufacturer)
- Table 3-2: Alzheimer’s Disease and Other Dementia Therapies in Development
- Table 3-3: The World Market for Alzheimer’s Disease and Other Dementias 2002-2009
- Figure 3-1: Alzheimer’s Disease and Other Dementias Market 2002-2009
- Table 3-4: Alzheimer’s Disease and Other Dementias Market Estimated Products Sales by Geographic Region, 2004
- Figure 3-2: Alzheimer’s Disease and Other Dementias Market Market Share by Geographic Region, 2004
- Table 3-5: Alzheimer’s Disease and Other Dementias Market Estimated Revenues and Market Share of Leading Suppliers 2004
- Figure 3-3: Alzheimer’s Disease and Other Dementias Market Estimated Market Share by Leading Suppliers 2004
- Table 3-6: Alzheimer’s Disease and Other Dementias Market Estimated Sales and Market Share of Top Products 2004
- Figure 3-4: Alzheimer’s Disease and Other Dementias Market Estimated Market Share of Top Products, 2004
Chapter Four: Brain and Neurologic Cancers
- Table 4-1: Currently Available Brain and Neurologic Cancer Treatments
- (Type, Brand, and Manufacturer)
- Table 4-2: Brain and Neurologic Cancer Treatments in Development
- Table 4-3: The Market for Brain and Neurologic Cancer Treatments 2002-2009
- Figure 4-1: Brain and Neurologic Cancer Treatments Market 2002-2009
- Table 4-4: Brain and Neurologic Cancer Treatments Market Estimated Products Sales by Geographic Region, 2004
- Figure 4-2: Brain and Neurologic Cancer Treatments Market Market Share by Geographic Region, 2004
- Table 4-5: Brain and Neurologic Cancer Treatments Market Estimated Revenues and Market Share of Leading Suppliers 2004
- Figure 4-3: Brain and Neurologic Cancer Treatments Market Estimated Market Share by Leading Suppliers 2004
- Table 4-6: Brain and Neurologic Cancer Treatments Market Estimated Sales and Market Share of Top Products 2004
- Figure 4-4: Brain and Neurologic Cancer Treatments Market Estimated Market Share of Top Products, 2004
Chapter Five: Brain Trauma and Stroke
- Table 5-1: Currently Available Brain Trauma and Stroke Treatments (Type,
- Brand, and Manufacturer)
- Table 5-2: Brain Trauma and Stroke Treatments in Development
- Table 5-3: The Market for Brain Trauma and Stroke Treatments 2002-2009 Compound Annual Growth Rate
- Figure 5-1: Brain Trauma and Stroke Treatments Market 2002-2009
- Table 5-4: Brain Trauma and Stroke Treatments Market Estimated Products Sales by Geographic Region, 2004
- Figure 5-2: Brain Trauma and Stroke Treatments Market Market Share by Geographic Region, 2004
- Table 5-5: Brain Trauma and Stroke Treatments Market Estimated Revenues and Market Share of Leading Suppliers 2004
- Figure 5-3: Brain Trauma and Stroke Treatments Market Estimated Market Share by Leading Suppliers 2004
Chapter Six: Movement Disorders
- Table 6-1: Currently Available Movement Disorder Treatments (Type, Brand, and Manufacturer)
- Table 6-2: Movement Disorder Treatments in Development
- Table 6-3: The Market for Movement Disorders 2002-2009
- Figure 6-1: Movement Disorder Market 2002-2009
- Table 6-4: Movement Disorder Market Estimated Products Sales by Geographic Region, 2004
- Figure 6-2: Movement Disorder Market Market Share by Geographic Region, 2004
- Table 6-5: Movement Disorder Market Estimated Revenues and Market Share of Leading Suppliers 2004
- Figure 6-3: Movement Disorder Market Estimated Market Share by Leading Suppliers 2004
- Table 6-6: Movement Disorder Market Estimated Sales of Top Products 2004
- Figure 6-4: Movement Disorder Market Estimated Market Share of Top Products, 2004
Chapter Seven: Seizure Disorders and Epilepsy
- Table 7-1: Currently Available Seizure Disorders and Epilepsy Treatments
- (Type, Brand, and Manufacturer)
- Table 7-2: Seizure Disorders and Epilepsy Treatments in Development
- Table 7-3: The Market for Seizure Disorders and Epilepsy 2002-2009
- Figure 7-1: Seizure Disorders and Epilepsy Market 2002-2009
- Table 7-4: Seizure Disorders and Epilepsy Market Estimated Products Sales by Geographic Region, 2004
- Figure 7-2: Seizure Disorders and Epilepsy Market Market Share by Geographic Region, 2004
- Table 7-5: Seizure Disorders and Epilepsy Market Estimated Revenues and Market Share of Leading Suppliers 2004
- Figure 7-3: Seizure Disorders and Epilepsy Market Estimated Market Share by Leading Suppliers 2004
- Table 7-6: Seizure Disorders and Epilepsy Market Estimated Sales of Top Products 2004
- Figure 7-4: Seizure Disorders and Epilepsy Market Estimated Market Share of Top Products, 2004
Chapter Eight: Spinal Cord and Peripheral Nerve Disorders
- Table 8-1: Currently Available Spinal Cord and Peripheral Nerve Disorder Treatments (Type, Brand, and Manufacturer)
- Table 8-2: Spinal Cord and Peripheral Nerve Disorder Treatments in Development
- Table 8-3: The Market for Spinal Cord and Peripheral Nerve Disorders 2002-2009
- Figure 8-1: Spinal Cord and Peripheral Nerve Disorder Market 2002-2009
- Table 8-4: Spinal Cord and Peripheral Nerve Disorder Market Estimated Products Sales by Geographic Region, 2004
- Figure 8-2: Spinal Cord and Peripheral Nerve Disorder Market Market Share by Geographic Region, 2004
- Table 8-5: Spinal Cord and Peripheral Nerve Disorder Market Estimated Revenues and Market Share of Leading Suppliers 2004
- Figure 8-3: Spinal Cord and Peripheral Nerve Disorder Market Estimated Market Share by Leading Suppliers 2004
- Table 8-6: Spinal Cord and Peripheral Nerve Disorder Market Estimated Sales of Top Products 2004
- Figure 8-4: Spinal Cord and Peripheral Nerve Disorder Market Estimated Market Share of Top Products, 2004
Chapter Nine: Other Neurological Conditions and Diseases
- Table 9-1: Currently Available Other Neurological Conditions and Disorders Treatments (Type, Brand, and Manufacturer)
- Table 9-2: Other Neurological Conditions and Disorders Treatments in Development
- Table 9-3: The Market for Other Neurological Conditions and Disorders 2002-2009
- Figure 9-1: Other Neurological Conditions and Disorders Market 2002-2009
- Table 9-4: Other Neurological Conditions and Disorders Market Estimated Products Sales by Geographic Region, 2004
- Figure 9-2: Other Neurological Conditions and Disorders Market Market Share by Geographic Region, 2004
- Table 9-5: Other Neurological Conditions and Disorders Market Estimated Revenues and Market Share of Leading Suppliers 2004
- Figure 9-3: Other Neurological Conditions and Disorders Market Estimated Market Share by Leading Suppliers 2004
- Table 9-6: Other Neurological Conditions and Disorders Market Estimated Sales of Top Products 2004
- Figure 9-4: Other Neurological Conditions and Disorders Market Estimated Market Share of Top Products, 2004
Chapter Eleven: Market Summary
- Table 11-1: The World Market for Neurotherapeutic Drugs 2002-2009
- Figure 11-1: The World Market for Neurotherapeutic Drugs 2002-2009
- Table 11-2: Worldwide Neurotherapeutic Drug Market by Type 2002-2009
- Figure 11-2: The World Market for Neurotherapeutic Drugs Revenues by Type 2002-2009
